Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 97 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Autistic Disorder in Children and Adolescents Clear all
Not listed Phase 2 Interventional

CASCADE: CAnnabidiol Study in Children With Autism Spectrum DisordEr

NCT04520685
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Oral cannabidiol 100mg/mL, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
5 Years to 17 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Jul 21, 2026, 11:01 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Facing Your Fears: Adolescents With ASD and Intellectual Disability

NCT05131425
View directory record Official record
Conditions
Autism Spectrum Disorder, Intellectual Disability, Anxiety, Emotion Regulation
Interventions
Facing Your Fears: ASD/ID, Treatment as Usual
Behavioral · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 18 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
2
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Jul 21, 2026, 11:01 AM EDT
Completed Phase 3 Interventional

Treatment of Autism in Children and Adolescents

NCT00005014
View directory record Official record
Conditions
Autistic Disorder
Interventions
Risperidone
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
5 Years to 17 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
5
States / cities
Los Angeles, California • New Haven, Connecticut • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2014 · Synced Jul 21, 2026, 11:01 AM EDT
Enrolling by invitation No phase listed Observational

Intranasal Insulin for Autism Spectrum Disorder in Children and Young Adults Aged 4 to 21 Years

NCT07521371
View directory record Official record
Conditions
Autism Spectrum Disorder, Autism Spectrum Disorder (ASD), Autism Spectrum Disorder High-Functioning, Autism Spectrum Disorder With Absence of Functional Language, Autism Spectrum Disorder With Impaired Functional Language, Autistic Disorder of Childhood Onset With Full Syndrome, Autistic Disorders Spectrum, Autistic Disorder, Autistic Disorder in Children and Adolescents, Neurodevelopmental Disorders, Neurodevelopmental Disorders (NDD), Neurodevelopmental Disorders and Developmental Abnormalities
Interventions
Not listed
Lead sponsor
Healing Hope International
Other
Eligibility
4 Years to 21 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Spring, Texas
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Jul 21, 2026, 11:01 AM EDT
Completed Not applicable Interventional

RUPP PI PDD: Drug and Behavioral Therapy for Children With Pervasive Developmental Disorders

NCT00080145
View directory record Official record
Conditions
Child Development Disorders, Pervasive
Interventions
Risperidone, Behavior Therapy
Drug · Behavioral
Lead sponsor
Yale University
Other
Eligibility
4 Years to 13 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
3
States / cities
New Haven, Connecticut • Indianapolis, Indiana • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 15, 2013 · Synced Jul 21, 2026, 11:01 AM EDT
Completed No phase listed Observational

The Effects of a Clean Room Sleeping Environment on Elemental and Chemical Concentrations in Children With Autism

NCT02195401
View directory record Official record
Conditions
Autism
Interventions
Cleanroom
Other
Lead sponsor
The Children's Institute
Other
Eligibility
3 Years to 21 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 20, 2014 · Synced Jul 21, 2026, 11:01 AM EDT
Not yet recruiting Phase 3 Interventional

A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder

NCT07285798
View directory record Official record
Conditions
Irritability Associated With Autism Spectrum Disorder
Interventions
KarXT, KarX-EC, KarXT + KarX-EC Matching Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
5 Years to 17 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
19
States / cities
Phoenix, Arizona • Glendale, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Jul 21, 2026, 11:01 AM EDT
Completed Phase 3 Interventional Results available

Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD).

NCT00332241
View directory record Official record
Conditions
Autistic Disorder
Interventions
Aripiprazole, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
9
States / cities
Boca Raton, Florida • Atlanta, Georgia • Louisville, Kentucky + 6 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Jul 21, 2026, 11:01 AM EDT
Completed Phase 3 Interventional Results available

Effectiveness of Atomoxetine in Treating ADHD Symptoms in Children and Adolescents With Autism

NCT00498173
View directory record Official record
Conditions
Autism
Interventions
Atomoxetine, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
5 Years to 15 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
2
States / cities
Indianapolis, Indiana • Lexington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Jul 21, 2026, 11:01 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Metabolic Processes in Adults and Adolescents With Autism Spectrum Disorder

NCT02733120
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
stable isotope infusion
Other
Lead sponsor
Texas A&M University
Other
Eligibility
16 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Jul 21, 2026, 11:01 AM EDT
Recruiting Not applicable Interventional

TF-CBT for Autistic Youth Pilot Implementation - Open Pilot

NCT07420478
View directory record Official record
Conditions
Autism Spectrum Disorder, PTSD and Trauma-related Symptoms, Autism, Trauma and Stressor Related Disorders, Mental Health Services
Interventions
Trauma-Focused Cognitive Behavioral Therapy, modified for autistic youth
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
6 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Jul 21, 2026, 11:01 AM EDT
Completed Phase 1 Interventional

Study of the Pharmacokinetics and Safety of Tasimelteon in Children and Adolescents

NCT02776215
View directory record Official record
Conditions
Circadian Rhythm Sleep Disorders, Non-24 Hour Sleep-Wake Disorder, Autism Spectrum Disorder, Smith-Magenis Syndrome
Interventions
tasimelteon
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
3 Years to 17 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Jul 21, 2026, 11:01 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Behavioral and Neural Response to Memantine in Adolescents With Autism Spectrum Disorder

NCT01972074
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Memantine, Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
8 Years to 17 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 30, 2024 · Synced Jul 21, 2026, 11:01 AM EDT
Completed Phase 2 Interventional Results available

Acamprosate in Youth With Fragile X Syndrome

NCT01300923
View directory record Official record
Conditions
Fragile X Syndrome, Autism Spectrum Disorders
Interventions
Acamprosate
Drug
Lead sponsor
Indiana University
Other
Eligibility
5 Years to 17 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced Jul 21, 2026, 11:01 AM EDT
Completed Phase 1 Interventional

Brain Imaging of Intranasal Oxytocin Treatment in Autism

NCT01945957
View directory record Official record
Conditions
Autism Spectrum Disorders
Interventions
Oxytocin
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
6 Years to 18 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 24, 2017 · Synced Jul 21, 2026, 11:01 AM EDT
Completed Phase 3 Interventional

Study of Fluoxetine in Autism

NCT00515320
View directory record Official record
Conditions
Autistic Disorder
Interventions
Fluoxetine, Placebo
Drug
Lead sponsor
Neuropharm
Industry
Eligibility
5 Years to 17 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
17
States / cities
Phoenix, Arizona • Sacramento, California • Gainesville, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2012 · Synced Jul 21, 2026, 11:01 AM EDT
Completed Phase 3 Interventional Results available

Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder

NCT04174365
View directory record Official record
Conditions
Irritability Associated With Autism Spectrum Disorder (ASD)
Interventions
Brexpiprazole, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
5 Years to 17 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Jul 21, 2026, 11:01 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Feasibility and Safety of a Virtual-Reality Based Job Interview Training Tool in Teenagers With High-Functioning Autism

NCT04773548
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
VR-JIT
Other
Lead sponsor
Kessler Foundation
Other
Eligibility
13 Years to 18 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 25, 2021 · Synced Jul 21, 2026, 11:01 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Autism-Related Irritability in Adolescents, Respectively

NCT07424404
View directory record Official record
Conditions
Schizophrenia, Autism-Related Irritability
Interventions
KarXT
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
5 Years to 17 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
51
States / cities
Dothan, Alabama • Phoenix, Arizona • Anaheim, California + 45 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 21, 2026, 11:01 AM EDT
Completed No phase listed Observational Results available

Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study

NCT01269710
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorder, Not Otherwise Specified, Prodromal Schizophrenia, Mood Disorder, Bipolar Disorder, Major Depressive Disorder, Depressive Disorder, Not Otherwise Specified, Mood Disorder, Not Otherwise Specified, Autism Spectrum Disorder
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
3 Years to 19 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 21, 2013 · Synced Jul 21, 2026, 11:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Scales for Repetitive and Restricted Behaviors in Children, Adolescents, and Adults With Autism Spectrum Disorder (ASD)

NCT03611075
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
No Intervention
Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
5 Years to 45 Years
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
15
States / cities
Dothan, Alabama • Phoenix, Arizona • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2022 · Synced Jul 21, 2026, 11:01 AM EDT
Completed Phase 3 Interventional Results available

Study of Aripiprazole in the Treatment of Serious Behavioral Problems in Children and Adolescents With Autistic Disorder (AD)

NCT00365859
View directory record Official record
Conditions
Autistic Disorder, Behavioral Symptoms
Interventions
Aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
55
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2013 · Synced Jul 21, 2026, 11:01 AM EDT
Completed Phase 2 Interventional Results available

Riluzole to Treat Child and Adolescent Obsessive-Compulsive Disorder With or Without Autism Spectrum Disorders

NCT00251303
View directory record Official record
Conditions
Obsessive-Compulsive Disorder, Autism Spectrum Disorder, Autism, Asperger Disorder, Developmental Disorder
Interventions
Riluzole, Placebo
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
7 Years to 17 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 14, 2014 · Synced Jul 21, 2026, 11:01 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Alpha Auditory Entrainment for Cognitive Enhancement and Sensory Hypersensitivity in Youth With Developmental Disorders

NCT06227780
View directory record Official record
Conditions
Fragile X Syndrome, Autism Spectrum Disorder, Autistic Disorder, Asperger Syndrome
Interventions
Alpha Auditory Entrainment, Sham
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
5 Years to 10 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Jul 21, 2026, 11:01 AM EDT